Pfizer Files Paediatric Lipitor With The EMEA

Multinational drugmaker Pfizer has filed a paediatric 5mg formulation of Lipitor (atorvastatin) with the European Medicines Agency (EMEA). The drug is indicated for the treatment of patients aged between six and 18 years old with familial hypercholesterolemia (FH), a rare genetic disorder that causes high LDL-cholesterol levels and increases the risk of heart disease. Pfizer has also developed a new chewable form of Lipitor, including a pediatric-appropriate 5mg dose, which is part of the submission. Lipitor has been approved for use in children aged 10 to 17 years old with heterozygous FH in the United States since 2002.

To read the full article, please choose one of the following options: